{
    "ticker": "TCBX",
    "name": "TC Biopharm",
    "description": "TC Biopharm is a clinical-stage biotechnology company focused on the development of cell therapy products for the treatment of cancer and infectious diseases. Founded in 2014, the company is at the forefront of innovative therapeutic solutions, leveraging its proprietary technology platform that utilizes T-cell therapies. TC Biopharm's lead product candidate, TCB-008, is designed to enhance the body's immune response against tumors and has shown promise in early-stage clinical trials. The company aims to address significant unmet medical needs in oncology by providing effective and targeted treatment options that can improve patient outcomes. With a commitment to advancing the field of immunotherapy, TC Biopharm collaborates with leading research institutions and clinical centers to accelerate the development and commercialization of its therapies. The company is headquartered in Glasgow, Scotland, and is committed to maintaining high standards of quality and compliance in its research and development processes. TC Biopharm's vision is to pioneer next-generation therapies that empower the immune system to fight cancer more effectively.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Glasgow, Scotland, UK",
    "founded": "2014",
    "website": "https://www.tcbiopharm.com",
    "ceo": "Michael McGarrity",
    "social_media": {
        "twitter": "https://twitter.com/tcbiopharm",
        "linkedin": "https://www.linkedin.com/company/tc-biopharm/"
    },
    "investor_relations": "https://www.tcbiopharm.com/investors",
    "key_executives": [
        {
            "name": "Michael McGarrity",
            "position": "CEO"
        },
        {
            "name": "David McGarry",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapy",
            "products": [
                "TCB-008",
                "TCB-007"
            ]
        }
    ],
    "seo": {
        "meta_title": "TC Biopharm | Innovative Cell Therapy Solutions",
        "meta_description": "Explore TC Biopharm, a leader in cell therapy development for cancer and infectious diseases. Discover our innovative therapeutics and commitment to patient care.",
        "keywords": [
            "TC Biopharm",
            "Cell Therapy",
            "Immunotherapy",
            "Biotechnology",
            "Cancer Treatment"
        ]
    },
    "faq": [
        {
            "question": "What is TC Biopharm known for?",
            "answer": "TC Biopharm is known for developing innovative cell therapy products for cancer and infectious diseases."
        },
        {
            "question": "Who is the CEO of TC Biopharm?",
            "answer": "Michael McGarrity is the CEO of TC Biopharm."
        },
        {
            "question": "Where is TC Biopharm headquartered?",
            "answer": "TC Biopharm is headquartered in Glasgow, Scotland, UK."
        },
        {
            "question": "What are TC Biopharm's main products?",
            "answer": "TC Biopharm's main products include TCB-008 and TCB-007, both of which are in development for cancer treatment."
        },
        {
            "question": "When was TC Biopharm founded?",
            "answer": "TC Biopharm was founded in 2014."
        }
    ],
    "competitors": [
        "NVS",
        "BMY",
        "GILD",
        "REGN"
    ],
    "related_stocks": [
        "AMGN",
        "VRTX",
        "INCY",
        "CELG"
    ]
}